Skip to Main Content

++

INTRODUCTION

++

salmeterol (sal-met-er-ole)

Serevent

Classification

Therapeutic: bronchodilators

Pharmacologic: adrenergics

++
Indications
++

Long-term control of reversible airway obstruction due to asthma and for maintenance treatment of asthma and prevention of bronchospasm. Prevention of exercise-induced asthma. Maintenance treatment to prevent bronchospasm in COPD, including chronic bronchitis and emphysema.

++
Action
++

Produces accumulation of cyclic adenosine monophosphate (cAMP) at beta2-adrenergic receptors. Relatively specific for beta (pulmonary) receptors. Therapeutic Effects: Bronchodilation.

++
Adverse Reactions/Side Effects
++

CNS: headache, nervousness. CV: palpitations, tachycardia. GI: abdominal pain, diarrhea, nausea. MS: muscle cramps/soreness. Neuro: trembling. Resp: paradoxical bronchospasm, cough.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Assess pulmonary function at rest and during exercise (See Appendices I, J, K) to document effectiveness of medication in controlling bronchospasm.

  • Watch for signs of paradoxical bronchospasm (wheezing, cough, dyspnea, tightness in chest and throat), especially at higher doses or during excessive use of the inhaler. If condition occurs, advise patient to withhold medication and notify physician or other health care professional immediately.

  • Assess heart rate, ECG, and heart sounds, especially during exercise (See Appendices G, H). Report a rapid heart rate (tachycardia) or signs of other arrhythmias, including palpitations, chest discomfort, shortness of breath, fainting, and fatigue/weakness.

  • Monitor and report signs of CNS toxicity, including nervousness or trembling. Sustained or severe CNS signs may indicate overdose or excessive use of this drug.

  • Assess any muscle cramps or soreness. Report severe or prolonged musculoskeletal symptoms.

++
Interventions
++

  • When implementing airway clearance techniques or respiratory muscle training, attempt to intervene when the airway is maximally bronchodilated. Peak responses typically occur about 3–4 hr after inhalation.

  • Because of the risk of cardiovascular stimulation, use caution during aerobic exercise and endurance conditioning. Cardiac effects should be minimal at lower doses or occasional inhaled use. Cardiovascular effects such as arrhythmias, angina pectoris, or increased blood pressure (BP) may occur at higher doses or during excessive use, and are caused by inadvertent stimulation of beta receptors on the heart.

++
Patient/Client-Related Instruction
++

  • Advise patient not to exceed the recommended dose or frequency of inhalations. Contact physician immediately if bronchospasm is not relieved by medication or is accompanied by diaphoresis, dizziness, or other symptoms.

  • Counsel patient on proper use of inhaler; observe use of this device whenever possible to ensure proper technique.

  • Instruct patient and family/caregivers to report severe or prolonged headache or GI problems (nausea, diarrhea, abdominal pain).

++
Pharmacokinetics
++

Absorption: Minimal systemic absorption follows inhalation.

++

Distribution: Action is primarily local.

++

Metabolism and Excretion: Unknown.

++

Half-life: 3–4 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (bronchodilation)

...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.